Wang Wenjia, Chen Donglai, Zhao Yuhuan, Zhao Ting, Wen Junmiao, Mao Yiming, Chen Chang, Sang Yonghua, Zhang Yongsheng, Chen Yongbing
Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai 200433, China.
Ann Transl Med. 2019 Dec;7(23):776. doi: 10.21037/atm.2019.11.38.
We aimed to characterize the relationships of lymphocyte activation gene-3 (LAG-3) expression, cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) expression, and CD8 tumor-infiltrating lymphocyte (TIL) density, and to investigate the joint prognostic impact of these three markers in patients with surgically resected esophageal squamous cell carcinoma (ESCC).
Expression of LAG-3, CTLA-4 and the density of CD8 TILs were evaluated by immunohistochemistry in resected ESCC. The associations between LAG-3 expression and clinicopathologic characteristics, as well as patient prognoses, were analyzed.
A total of 183 patients were included. LAG-3 expression was observed in 69 (37.7%) patients. Positive LAG-3 expression was significantly associated with CTLA-4 expression (P=0.004). LAG-3 positivity, CTLA-4 positivity, and low CD8 TIL densities were significantly associated with worsening recurrence-free survival (RFS) [LAG-3: hazard ratio (HR), 1.72; 95% confidence interval (CI), 1.10-2.89; P=0.019; CTLA-4: HR, 1.69; 95% CI, 1.04-2.73; P=0.033; CD8: HR, 0.60; 95% CI, 0.38-0.94; P=0.025] and overall survival (OS) (LAG-3: HR, 2.09; 95% CI, 1.24-3.53; P=0.006; CTLA-4: HR, 1.47; 95% CI, 0.86-2.53; P=0.161; CD8: HR, 0.56; 95% CI, 0.33-0.95; P=0.032). Subgroup analysis revealed that the LAG-3 CTLA-4 CD8 group had the best RFS (P<0.001) and OS (P<0.001).
LAG-3 expression was correlated with CTLA-4 expression on TILs. Positive LAG-3 expression was associated with poor prognoses in ESCC. A combination of LAG-3, CTLA-4 expression and CD8 TILs density could further stratify patients into different subgroups with distinct prognoses.
我们旨在描述淋巴细胞激活基因-3(LAG-3)表达、细胞毒性T淋巴细胞相关抗原4(CTLA-4)表达与CD8肿瘤浸润淋巴细胞(TIL)密度之间的关系,并研究这三个标志物对手术切除的食管鳞状细胞癌(ESCC)患者的联合预后影响。
通过免疫组织化学评估切除的ESCC中LAG-3、CTLA-4的表达及CD8 TILs的密度。分析LAG-3表达与临床病理特征以及患者预后之间的关联。
共纳入183例患者。69例(37.7%)患者观察到LAG-3表达。LAG-3阳性表达与CTLA-4表达显著相关(P=0.004)。LAG-3阳性、CTLA-4阳性及低CD8 TIL密度与无复发生存期(RFS)恶化显著相关[LAG-3:风险比(HR),1.72;95%置信区间(CI),1.10-2.89;P=0.019;CTLA-4:HR,1.69;95% CI,1.04-2.73;P=0.033;CD8:HR,0.60;95% CI,0.38-0.94;P=0.025]及总生存期(OS)(LAG-3:HR,2.09;95% CI,1.24-3.53;P=0.006;CTLA-4:HR,1.47;95% CI,0.86-2.53;P=0.161;CD8:HR,0.56;95% CI,0.33-0.95;P=0.032)。亚组分析显示,LAG-3 CTLA-4 CD8组的RFS(P<0.001)和OS(P<0.001)最佳。
LAG-3表达与TILs上的CTLA-4表达相关。LAG-3阳性表达与ESCC患者的不良预后相关。LAG-3、CTLA-4表达及CD8 TILs密度的联合可进一步将患者分层为具有不同预后的不同亚组。